A Phase 1/2a, Open-label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of BMS-986528 in Participants With Refractory Rheumatoid Arthritis
Latest Information Update: 25 Feb 2026
At a glance
- Drugs BMS 986528 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
Most Recent Events
- 25 Feb 2026 New trial record